GSK & Sanofi’s Unprecedented COVID-19 Vaccine Collaboration
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
Expanscience is a family owned, independent French pharmaceutical and dermo-cosmetics laboratory, developing and manufacturing innovative osteoarthritis and skincare products. The company’s products, including two leading brands including Piascledine 300 and Mustela, are sold in more than 100 countries. With over 60 years of experience, Expanscience has built up a solid international reputation as an innovator and a specialist. The company prides itself in developing and marketing with active ingredients of natural origin for the French and international cosmetics industry. Thanks to a robust Corporate Social Responsibility program introduced over ten years ago, the company has made strong efforts in developing a sustainable and environmentally conscious business practice which has been recognized as exemplary by the AFAQ 26000 assessment in 2013. With a company motto: “Protecting Your Health Through Innovation,” Expanscience innovates to develop safe and effective solutions that do not harm people or the environment so that everyone can avoid osteoarthritis and skin problems.
Contact
10 avenue de l’Arche
92419 – Courbevoie
France
Tel : +33 (0)1 43 34 60 00
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
Speaking exclusively to PharmaBoardroom at the International Women’s Day 2020 event at the Franco-British Chamber of Commerce in Paris, esteemed cardiologist Professor Claire Mounier-Vehier outlines why cardiovascular disease is not…
Researchers at the Institut Pasteur in Paris have become the first in Europe to fully sequence the genome of the 2019-nCoV coronavirus – putting the Institut at the forefront of…
These are worrying times for iconic French mid-cap Ipsen. Trials for palovarotene, a treatment for rare bone disorders, have been plagued by setbacks, perhaps contributing to erstwhile CEO David Meek’s…
France is home to the highest rates of vaccine mistrust in Europe, with a third of French people disagreeing that vaccines are safe, according to the Wellcome Global Monitor survey.…
With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing…
France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with top-class institutions, a dense network of…
With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a…
Francois Cornu, president of Eurofins Biomnis, and Gautier Decock, managing director of Eurofins BioPharma Product Testing in France and Belgium, come together to shed light on the company’s unique decentralized…
Nathalie Giraud, director of integrated monitoring investigator services & head of France at PPD, breaks down the strengths and weaknesses of the French clinical trials environment and stresses the importance…
The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain…
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but…
See our Cookie Privacy Policy Here
